Myriad Genetics Q2 revenue down 11% to $190.7M; revises FY2026 guidance lower, suspends EBITDA guidance

MYRIAD GENETICS INC

Q2 revenue $190.7M (-11% YoY); test volumes 379K flat; avg revenue per test down 9% including $11M prior-period estimate adjustment.
Gross margin 66.6% (-460 bps); operating loss $38.9M; cash $115.2M.
FY2026 revenue guidance revised to $770-790M; adjusted gross margin 66-67%; suspended Adjusted EBITDA guidance.
Cancer Care Continuum volume up 6% but revenue down 11%; Prenatal Health volume down 9%; Mental Health volume up 4% but revenue down 3%.
Launched Ascend efficiency initiative; evaluating portfolio; launched Prolaris+AI and FirstGene prenatal screen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.